Endocrinology and Metabolism Market Research Report Information By Therapy Area (Diabetes Drugs, HGH, Thyroid Hormone Disorders, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) – Market Forecast Till 2032

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3.Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Data Mining

3.3. Secondary Research

3.4. Primary Research

3.4.1. Primary Interviews and Information Gathering Process

3.4.2.Breakdown of Primary Respondents

3.5. Forecasting Model

3.6. Market Size Estimation

3.6.1. Bottom-Up Approach

3.6.2. Top-Down Approach

3.7. Data Triangulation

3.8. Validation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Value Chain Analysis

5.2. Porter’s Five Forces Analysis

5.2.1. Bargaining Power of Suppliers

5.2.2. Bargaining Power of Buyers

5.2.3. Threat of New Entrants

5.2.4. Threat of Substitutes

5.2.5. Intensity of Rivalry

5.3. COVID-19 Impact Analysis

5.3.1. Market Impact Analysis

5.3.2. Regional Impact

5.3.3. Opportunity and Threat Analysis

6. GLOBAL ENDOCRINOLOGY AND METABOLISM MARKET, BY THERAPY AREA

6.1. Overview

6.2. Diabetes drugs

6.3. HGH

6.4. Thyroid hormone disorders

6.5. Others

7. GLOBAL ENDOCRINOLOGY AND METABOLISM MARKET, BY DISTRIBUTION CHANNEL

7.1. Overview

7.2. Hospital pharmacies

7.3. Retail pharmacies

7.4. Online pharmacies

8. GLOBAL ENDOCRINOLOGY AND METABOLISM MARKET, BY REGION

8.1. Overview

8.1. North America

8.1.1. US

8.1.2. Canada

8.2. Europe

8.2.1. Germany

8.2.2. France

8.2.3. UK

8.2.4. Italy

8.2.5. Spain

8.2.6. Rest of Europe

8.3. Asia-Pacific

8.3.1. China

8.3.2. India

8.3.3. Japan

8.3.4. South Korea

8.3.5. Australia

8.3.6. Rest of Asia-Pacific

8.4. Rest of the World

8.4.1. Middle East

8.4.2. Africa

8.4.3. Latin America

9. COMPETITIVE LANDSCAPE

9.1. Overview

9.2. Competitive Analysis

9.3. Market Share Analysis

9.4. Major Growth Strategy in the Global Endocrinology and Metabolism Market

9.5. Competitive Benchmarking

9.6. Leading Players in Terms of Number of Developments in the Global Endocrinology and Metabolism Market

9.7. Key Developments and Growth Strategies

9.7.1. New Product Launch/Service Deployment

9.7.2. Merger & Acquisitions

9.7.3. Joint Ventures

9.8. Major Players Financial Matrix

9.8.1. Sales & Operating Income, 2023

9.8.2. Major Players R&D Expenditure, 2023

10. COMPANY PROFILES

10.1. Abbott Laboratories

10.1.1. Company Overview

10.1.2. Financial Overview

10.1.3. Products Offered

10.1.4. Key Developments

10.1.5. SWOT Analysis

10.1.6. Key Strategies

10.2. Acerus Pharmaceuticals Corp.

10.2.1. Company Overview

10.2.2. Financial Overview

10.2.3. Products Offered

10.2.4. Key Developments

10.2.5. SWOT Analysis

10.2.6. Key Strategies

10.3. Bayer AG

10.3.1. Company Overview

10.3.2. Financial Overview

10.3.3. Products Offered

10.3.4. Key Developments

10.3.5. SWOT Analysis

10.3.6. Key Strategies

10.4. Eli Lilly and Co.

10.4.1. Company Overview

10.4.2. Financial Overview

10.4.3. Products Offered

10.4.4. Key Developments

10.4.5. SWOT Analysis

10.4.6. Key Strategies

10.5. Ascendis Pharma AS

10.5.1. Company Overview

10.5.2. Financial Overview

10.5.3. Products Offered

10.5.4. Key Developments

10.5.5. SWOT Analysis

10.5.6. Key Strategies

10.6. Endo International Plc

10.6.1. Company Overview

10.6.2. Financial Overview

10.6.3. Products Offered

10.6.4. Key Developments

10.6.5. SWOT Analysis

10.6.6. Key Strategies

10.7. F. Hoffmann La Roche Ltd.

10.7.1. Company Overview

10.7.2. Financial Overview

10.7.3. Products Offered

10.7.4. Key Developments

10.7.5. SWOT Analysis

10.7.6. Key Strategies

10.8. Biocon Ltd.

10.8.1. Company Overview

10.8.2. Financial Overview

10.8.3. Products Offered

10.8.4. Key Developments

10.8.5. SWOT Analysis

10.8.6. Key Strategies

10.9. GlaxoSmithKline Plc.

10.9.1. Company Overview

10.9.2. Financial Overview

10.9.3. Products Offered

10.9.4. Key Developments

10.9.5. SWOT Analysis

10.9.6. Key Strategies

10.10. Ipsen Pharma.

10.10.1. Company Overview

10.10.2. Financial Overview

10.10.3. Products Offered

10.10.4. Key Developments

10.10.5. SWOT Analysis

10.10.6. Key Strategies

10.11. Beta Cell NV

10.11.1. Company Overview

10.11.2. Financial Overview

10.11.3. Products Offered

10.11.4. Key Developments

10.11.5. SWOT Analysis

10.11.6. Key Strategies

10.12. Hanmi Pharm Co. Ltd.

10.12.1. Company Overview

10.12.2. Financial Overview

10.12.3. Products Offered

10.12.4. Key Developments

10.12.5. SWOT Analysis

10.12.6. Key Strategies

11. APPENDIX

11.1. References

11.2. Related Reports

LIST OF TABLES

TABLE 1 GLOBAL ENDOCRINOLOGY AND METABOLISM MARKET, SYNOPSIS, 2019-2032

TABLE 2 GLOBAL ENDOCRINOLOGY AND METABOLISM MARKET, ESTIMATES & FORECAST, 2019-2032 (USD BILLION)

TABLE 3 GLOBAL ENDOCRINOLOGY AND METABOLISM MARKET, BY THERAPY AREA, 2019-2032 (USD BILLION)

TABLE 4 GLOBAL ENDOCRINOLOGY AND METABOLISM MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)

TABLE 5 NORTH AMERICA: ENDOCRINOLOGY AND METABOLISM MARKET, BY THERAPY AREA, 2019-2032 (USD BILLION)

TABLE 6 NORTH AMERICA: ENDOCRINOLOGY AND METABOLISM MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)

TABLE 7 US: ENDOCRINOLOGY AND METABOLISM MARKET, BY THERAPY AREA, 2019-2032 (USD BILLION)

TABLE 8 US: ENDOCRINOLOGY AND METABOLISM MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)

TABLE 9 CANADA: ENDOCRINOLOGY AND METABOLISM MARKET, BY THERAPY AREA, 2019-2032 (USD BILLION)

TABLE 10 CANADA: ENDOCRINOLOGY AND METABOLISM MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)

TABLE 1 EUROPE: ENDOCRINOLOGY AND METABOLISM MARKET, BY THERAPY AREA, 2019-2032 (USD BILLION)

TABLE 2 EUROPE: ENDOCRINOLOGY AND METABOLISM MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)

TABLE 3 GERMANY: ENDOCRINOLOGY AND METABOLISM MARKET, BY THERAPY AREA, 2019-2032 (USD BILLION)

TABLE 4 GERMANY: ENDOCRINOLOGY AND METABOLISM MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)

TABLE 5 FRANCE: ENDOCRINOLOGY AND METABOLISM MARKET, BY THERAPY AREA, 2019-2032 (USD BILLION)

TABLE 6 FRANCE: ENDOCRINOLOGY AND METABOLISM MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)

TABLE 7 ITALY: ENDOCRINOLOGY AND METABOLISM MARKET, BY THERAPY AREA, 2019-2032 (USD BILLION)

TABLE 8 ITALY: ENDOCRINOLOGY AND METABOLISM MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)

TABLE 9 SPAIN: ENDOCRINOLOGY AND METABOLISM MARKET, BY THERAPY AREA, 2019-2032 (USD BILLION)

TABLE 10 SPAIN: ENDOCRINOLOGY AND METABOLISM MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)

TABLE 11 UK: ENDOCRINOLOGY AND METABOLISM MARKET, BY THERAPY AREA, 2019-2032 (USD BILLION)

TABLE 12 UK: ENDOCRINOLOGY AND METABOLISM MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)

TABLE 13 REST OF EUROPE: ENDOCRINOLOGY AND METABOLISM MARKET, BY THERAPY AREA, 2019-2032 (USD BILLION)

TABLE 14 REST OF EUROPE: ENDOCRINOLOGY AND METABOLISM MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)

TABLE 15 ASIA-PACIFIC: ENDOCRINOLOGY AND METABOLISM MARKET, BY THERAPY AREA, 2019-2032 (USD BILLION)

TABLE 16 ASIA-PACIFIC: ENDOCRINOLOGY AND METABOLISM MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)

TABLE 17 JAPAN: ENDOCRINOLOGY AND METABOLISM MARKET, BY THERAPY AREA, 2019-2032 (USD BILLION)

TABLE 18 JAPAN: ENDOCRINOLOGY AND METABOLISM MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)

TABLE 19 CHINA: ENDOCRINOLOGY AND METABOLISM MARKET, BY THERAPY AREA, 2019-2032 (USD BILLION)

TABLE 20 CHINA: ENDOCRINOLOGY AND METABOLISM MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)

TABLE 21 INDIA: ENDOCRINOLOGY AND METABOLISM MARKET, BY THERAPY AREA, 2019-2032 (USD BILLION)

TABLE 22 INDIA: ENDOCRINOLOGY AND METABOLISM MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)

TABLE 23 AUSTRALIA: ENDOCRINOLOGY AND METABOLISM MARKET, BY THERAPY AREA, 2019-2032 (USD BILLION)

TABLE 24 AUSTRALIA: ENDOCRINOLOGY AND METABOLISM MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)

TABLE 25 SOUTH KOREA: ENDOCRINOLOGY AND METABOLISM MARKET, BY THERAPY AREA, 2019-2032 (USD BILLION)

TABLE 26 SOUTH KOREA: ENDOCRINOLOGY AND METABOLISM MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)

TABLE 27 REST OF ASIA-PACIFIC: ENDOCRINOLOGY AND METABOLISM MARKET, BY THERAPY AREA, 2019-2032 (USD BILLION)

TABLE 28 REST OF ASIA-PACIFIC: ENDOCRINOLOGY AND METABOLISM MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)

TABLE 29 REST OF THE WORLD: ENDOCRINOLOGY AND METABOLISM MARKET, BY THERAPY AREA, 2019-2032 (USD BILLION)

TABLE 30 REST OF THE WORLD: ENDOCRINOLOGY AND METABOLISM MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)

TABLE 31 MIDDLE EAST: ENDOCRINOLOGY AND METABOLISM MARKET, BY THERAPY AREA, 2019-2032 (USD BILLION)

TABLE 32 MIDDLE EAST: ENDOCRINOLOGY AND METABOLISM MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)

TABLE 33 AFRICA: ENDOCRINOLOGY AND METABOLISM MARKET, BY THERAPY AREA, 2019-2032 (USD BILLION)

TABLE 34 AFRICA: ENDOCRINOLOGY AND METABOLISM MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)

TABLE 35 LATIN AMERICA: ENDOCRINOLOGY AND METABOLISM MARKET, BY THERAPY AREA, 2019-2032 (USD BILLION)

TABLE 36 LATIN AMERICA: ENDOCRINOLOGY AND METABOLISM MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL ENDOCRINOLOGY AND METABOLISM MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL ENDOCRINOLOGY AND METABOLISM MARKET

FIGURE 4 GLOBAL ENDOCRINOLOGY AND METABOLISM MARKET, SHARE (%), BY THERAPY AREA, 2023

FIGURE 5 GLOBAL ENDOCRINOLOGY AND METABOLISM MARKET, SHARE (%), BY DISTRIBUTION CHANNEL, 2023

FIGURE 6 GLOBAL ENDOCRINOLOGY AND METABOLISM MARKET, SHARE (%), BY REGION, 2023

FIGURE 7 NORTH AMERICA: ENDOCRINOLOGY AND METABOLISM MARKET, SHARE (%), BY REGION, 2023

FIGURE 8 EUROPE: ENDOCRINOLOGY AND METABOLISM MARKET, SHARE (%), BY REGION, 2023

FIGURE 9 ASIA-PACIFIC: ENDOCRINOLOGY AND METABOLISM MARKET, SHARE (%), BY REGION, 2023

FIGURE 10 REST OF THE WORLD: ENDOCRINOLOGY AND METABOLISM MARKET, SHARE (%), BY REGION, 2023

FIGURE 11 GLOBAL ENDOCRINOLOGY AND METABOLISM MARKET: COMPANY SHARE ANALYSIS, 2023 (%)

FIGURE 12 ABBOTT LABORATORIES: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 13 ABBOTT LABORATORIES: SWOT ANALYSIS

FIGURE 14 ACERUS PHARMACEUTICALS CORP.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 15 ACERUS PHARMACEUTICALS CORP.: SWOT ANALYSIS

FIGURE 16 BAYER AG: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 17 BAYER AG: SWOT ANALYSIS

FIGURE 18 ELI LILLY AND CO.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 19 ELI LILLY AND CO.: SWOT ANALYSIS

FIGURE 20 BIOCON LTD.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 21 BIOCON LTD.: SWOT ANALYSIS

FIGURE 22 ASCENDIS PHARMA AS: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 23 ASCENDIS PHARMA AS: SWOT ANALYSIS

FIGURE 24 F. HOFFMANN LA ROCHE LTD.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 25 F. HOFFMANN LA ROCHE LTD.: SWOT ANALYSIS

FIGURE 26 GLAXOSMITHKLINE PLC: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 27 GLAXOSMITHKLINE PLC: SWOT ANALYSIS

FIGURE 28 IPSEN PHARMA: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 29 IPSEN PHARMA: SWOT ANALYSIS

FIGURE 30 ENDO INTERNATIONAL PLC: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 31 ENDO INTERNATIONAL PLC: SWOT ANALYSIS

FIGURE 32 BETA CELL NV: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 33 BETA CELL NV: SWOT ANALYSIS

FIGURE 34 HANMI PHARM CO. LTD.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 35 HANMI PHARM CO. LTD.: SWOT ANALYSIS